Following the release of upbeat data and given some recent signs of stabilization in the stocks, MarketWatch took at look at companies in the healthcare sector that are expected to produce the fastest ...

TD Cowen has lowered Eli Lilly’s price target from $1,050 to $960, but maintained a Buy rating, citing solid long-term ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Erste Group has downgraded Eli Lilly from a buy to a hold rating due to concerns about its earnings forecast. Despite 36.38% ...

Now, let's return to our question: Should you invest $1,000 in Lilly right now? The shares are trading for 34 times forward ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Eli Lilly (NYSE: LLY) has been a growth beast over the years and is now easily the most valuable healthcare company in the ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Eli Lilly: "I just think this is a decent level ... Red Cat: "It's just one darn crazy stock. But I will tell you, it's not making any money." Rocket Companies: "I think Rocket's a very fine ...

Shareholders of Eli Lilly (Symbol: LLY) looking to boost their income beyond the stock's 0.8% annualized dividend yield can sell the June 2027 covered call at the $1000 strike and collect the ...

Despite recent headwinds at present, the stock's outlook remains promising. Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it.